Montag A & Associates Inc. Has $4.12 Million Holdings in Danaher Corporation (NYSE:DHR)

Montag A & Associates Inc. lessened its stake in shares of Danaher Corporation (NYSE:DHR - Free Report) by 28.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,062 shares of the conglomerate's stock after selling 8,037 shares during the period. Montag A & Associates Inc.'s holdings in Danaher were worth $4,119,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of DHR. Bank Pictet & Cie Europe AG lifted its stake in Danaher by 22.8% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 192,731 shares of the conglomerate's stock worth $44,241,000 after acquiring an additional 35,730 shares in the last quarter. Proficio Capital Partners LLC raised its stake in shares of Danaher by 28.0% during the 4th quarter. Proficio Capital Partners LLC now owns 2,566 shares of the conglomerate's stock worth $589,000 after purchasing an additional 562 shares in the last quarter. Blueshift Asset Management LLC purchased a new stake in shares of Danaher during the 4th quarter worth about $284,000. Millstone Evans Group LLC purchased a new stake in shares of Danaher during the 4th quarter worth about $101,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Danaher during the 4th quarter worth about $2,849,000. Institutional investors and hedge funds own 79.05% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the company. TD Cowen raised their price objective on Danaher from $240.00 to $248.00 and gave the company a "buy" rating in a research note on Wednesday, April 23rd. Barclays reissued an "overweight" rating and issued a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. HSBC cut their price objective on Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a research note on Friday, July 11th. Finally, Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research note on Friday, June 27th. Three analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $248.48.

Danaher Stock Down 2.5%

NYSE:DHR opened at $189.98 on Friday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The company has a market cap of $135.96 billion, a PE ratio of 36.89, a PEG ratio of 2.67 and a beta of 0.77. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70. The stock has a 50-day simple moving average of $196.13 and a 200 day simple moving average of $205.03.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings data on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.62 by $0.26. Danaher had a return on equity of 10.80% and a net margin of 15.81%. The business had revenue of $5.74 billion during the quarter, compared to the consensus estimate of $5.58 billion. On average, sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.67%. Danaher's dividend payout ratio is currently 24.85%.

Insider Activity at Danaher

In related news, Chairman Steven M. Rales sold 1,250,000 shares of the business's stock in a transaction on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman directly owned 3,105,808 shares in the company, valued at $611,036,665.92. The trade was a 28.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Christopher Paul Riley sold 15,805 shares of the business's stock in a transaction on Wednesday, April 30th. The shares were sold at an average price of $198.00, for a total value of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares of the company's stock, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.10% of the company's stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.